Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...